Archives — July 2016 back to current month (27)
Money Always Moves from Weak Hands into Strong Hands (07/31/2016)
Precious metals expert Bob Moriarty advises investors on how they can avoid the disinformation and invest with the smart money.
Oil Shares Now Attractive for the Long Term (07/30/2016)
Technical analyst Jack Chan charts a new major buy signal for oil stocks.
Gold Equity Correction Overdue (07/30/2016)
Technical analyst Jack Chan foresees a gold bull market correction, which he believes would make an excellent entry point.
What Experts Predict for the New Silver Bull Market (07/27/2016)
By the reckoning of market watchers, the silver bull has arrived. The Gold Report takes a look at what some of the experts predict for the silver price going forward and for companies poised to benefit from the upswing.
Remembering Gold's Bullish Set-Up on Dec. 1, 2015 (07/25/2016)
Precious metals expert Michael Ballanger compares the Dec. 1, 2015 Gold COT Report with the latest one; the contrasts could not be greater.
The US Dollar's Impact on Gold and Silver (07/23/2016)
Technical analyst Jack Chan charts a breakout of the U.S. dollar and comments on its implications for gold and silver.
Six Mining Companies to Watch as M&A Heats Up (07/22/2016)
Precious metals prices have gained momentum since the start of this year, and corporate M&A activity is heating up again. Caesars Report's Thibaut Lepouttre highlights a handful of mining companies with market capitalizations attractive to larger companies looking to boost their project pipelines.
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy.
Announcements of increased production at Trevali Mining Corp.'s Santander mine and the start of commercial production at Caribou mine, coupled with zinc inventories that remain at multiyear lows, have helped solidify the company's growth story.
Analysts with Paradigm Capital selected a quartet of oil and natural gas companies and one energy services company to highlight in the firm's recently released Top Quarterly Picks Q3/16 report.
Ups and Downs in Oil and Gold (07/16/2016)
Technical analyst Jack Chan charts a major buy signal in oil and a possible correction in gold.
Gold and Base Metals Top Picks from Paradigm Capital (07/14/2016)
Paradigm Capital's top picks for Q3/16 include gold and zinc mining companies with upcoming catalysts worthy of investors' attention.
The Broad Market, Helicopters and Gold (07/14/2016)
There has been a stunning post Brexit turnaround in the markets, says technical analyst Clive Maund. Far from leading to chaos, the markets have taken it in their stride, and are now rising in anticipation of "helicopter money."
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative.
Three Companies from a Winning Team (07/12/2016)
The very best way of betting on future success of a junior mining team is to measure what they have done over the past 15 years, says Bob Moriarty, and he discusses three companies that have had the same winning management team.
Precious metals expert Michael Ballanger discusses the relationship of rising money velocity, money printing and new stock market highs.
Reservoir Minerals Goes Out in Glory (07/11/2016)
Money manager Adrian Day updates the conclusion of the saga of Nevsun Resources' acquisition of Reservoir Minerals.
Brexit Leads to Uncertainty, But It's Good for Gold (07/11/2016)
The Brexit vote adds uncertainty to an already turbulent global environment, says money manager Adrian Day, and has helped gold resume its rally.
The long-term outlook for silver is very positive indeed, but over the short to medium term it looks set to react, says technical analyst Clive Maund.
Gold Bull Confirmed: What's Next? (07/09/2016)
Technical analyst Jack Chan confirms a bull market for gold and lays out his investment strategy.
Torchlight Energy recently updated investors as to scientific information returned from third-party providers who performed testing on its University Founders B-19 #1 well. Results were overwhelmingly positive and reflect the substantial upside opportunity in the wildcatter-stage E&P.
Gold Heading Toward $1,400 As Bull Run Commences (07/06/2016)
Gold's post-Brexit vote surge continues unabated, with Bloomberg reporting today that the price of the safe haven commodity has risen for six consecutive days.
Assay results from Newmarket Gold's Harrier South gold system have confirmed the potential for expansion at the company's Fosterville Gold Mine in Australia.
Seabridge closed on its SnipGold acquisition last week in British Columbia's "Golden Triangle," a transaction that Canaccord Genuity says has potential for a large impact.
Howard Flinker has been managing money for a long time and is always on the lookout for cyclical opportunities. Right now gold and silver companies are on his radar. Increasing demand from Asia and shrinking supply make this a prime time to focus on precious metals. In this interview with The Gold Report, Flinker details three companies in his portfolio poised to deliver outsized returns, including one that is bitcoin for gold.
Shining a Light on Torchlight Energy (07/05/2016)
Bob Moriarty calculates the more-than-tenbagger value proposition of a small energy company operating in the Orogrande and Midland Basins in Texas.
Buy Signals in Place for Gold, Silver, Oil (07/04/2016)
Technical analyst Jack Chan charts major buy signals for gold, silver and oil.
|"GSV is well-positioned for growth through exploration."|
|"PVG remains on track for production of gold in the coming weeks."|
|"ALK's Q3/17 report indicates a complete turnaround at Tomingley."|
|"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."|
|"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."|